You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昆藥集團(600422.SH)擬向銀諾醫藥提供借款5000萬元 支持研發蘇帕魯肽注射液
格隆匯 02-05 18:12

格隆匯2月5日丨昆藥集團(600422.SH)公佈,公司擬向昆明銀諾醫藥技術有限公司(以下簡稱“銀諾醫藥”)提供借款5000萬元人民幣,期限為1年,年利率為8%。借款用途為蘇帕魯肽注射液研發項目支出。

蘇帕魯肽注射液是銀諾醫藥開發的一種針對2型糖尿病的長效降糖藥,是一種用基因工程重組蛋白技術製作生產的創新生物藥。目前蘇帕魯肽注射液研發項目處於I期臨牀結題等報告階段。

銀諾醫藥的其他兩位股東QINGHUA WANG與香港醫韻醫藥技術有限公司(以下合稱“丙方”)按其等在銀諾醫藥合計持股比例(即49%),為銀諾醫藥對該借款形成的債務總額(包括但不限於借款本息)的償還,共同向公司承擔連帶保證擔保責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account